Targeting FCRLA to induce necrosis in lung adenocarcinoma: a novel strategy for prognosis and therapy via MPT-Driven pathways.

Xiaoli Sun, Bowen Cai, Shusen Zhang, Xiaowei Cao, Zhen Wang, Zhigang Cai

Abstract read

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoli SunThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Bowen CaiDepartment of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Shusen ZhangDepartment of Pulmonary and Critical Care Medicine, Xing tai People's Hospital, Xingtai, Hebei, China.

Xiaowei CaoDepartment of Pulmonary and Critical Care Medicine, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China.

Zhen WangDepartment of Pulmonary and Critical Care Medicine, Shijiazhuang People's Hospital, Shijiazhuang, Hebei, China.

Zhigang CaiThe First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The induction of mitochondrial permeability transition-driven necrosis (MPTDN) is therapeutically relevant in various cancers. However, few studies have explored the role of MPTDN-related genes (MPTDNRGs) in lung adenocarcinoma (LUAD). Therefore, this study investigated the regulatory mechanisms of MPTDNRGs in LUAD. Methods: This study was based on The Cancer Genome Atlas-Lung Adenocarcinoma (TCGA-LUAD), GSE31210, and MPTDNRGs. First, the genes obtained from TCGA-LUAD were intersected through differential expression analysis and weighted gene co-expression network analysis (WGCNA) to obtain the candidate Results: A total of 82 candidate genes were identified by intersecting 3,231 differentially expressed genes with 566 key module genes. Subsequently, three prognostic genes ( Discussion:

Indexed as

Adenocarcinoma of LungLung NeoplasmsApoptosisCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMembrane Potential, MitochondrialMitochondriaNecrosisPrognosisSignal TransductionFCRLAlung adenocarcinomamitochondrial permeability transition driven necrosisnew strategyrisk model

Identifiers

PMID40881693

DOI10.3389/fimmu.2025.1596179

PMCPMC12380818

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.